Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Prior art considerations when patenting DNA sequences

Prior disclosure of corresponding protein sequences or uncharacterized DNA sequences may impact your chances to patent a newly discovered DNA.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Amgen Inc. v. Chugai Pharmaceutical Co., Ltd., 9 USPQ2d 1833 (D. Mass. 1989); 18 USPQ2d 1016 (Fed. Cir. 1991).

  2. In re Bell 26 USPQ2d 1529 (Fed. Cir. 1993).

  3. In re Deuel 34 USPQ2d 1210 (Fed. Cir. 1995).

  4. In re Deuel, 34 USPQ2d at 1215.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agris, C. Prior art considerations when patenting DNA sequences. Nat Biotechnol 14, 1309–1310 (1996). https://doi.org/10.1038/nbt1096-1309

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1096-1309

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing